免疫检查点抑制剂抗肿瘤治疗与HBV 再激活的关系.
陈顺， 解有成， 王俊科， 赵宝银… - Journal of Clinical …, 2023 - search.ebscohost.com
近年来, 免疫检查点抑制剂(ICI) 单药和联合治疗在从实体瘤到淋巴瘤等多种恶性肿瘤中取得了
广泛的疗效, 并且成为了多种癌症的标准化和系统化治疗模式. 然而, 在HBV …
广泛的疗效, 并且成为了多种癌症的标准化和系统化治疗模式. 然而, 在HBV …
Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation
C Shun, XIE Youcheng, J ZHANG, YU Xiaohui - 临床肝胆病杂志, 2023 - lcgdbzz.org
In recent years, monotherapy and combination therapy with immune checkpoint inhibitors
(ICIs) have achieved good efficacy in a variety of malignancies from solid tumors to …
(ICIs) have achieved good efficacy in a variety of malignancies from solid tumors to …
基础慢性肝脏疾病对接受免疫检查点抑制剂治疗的肿瘤患者的疗效及安全性的影响.
刘丹， 姚甜甜， 张宇涵， 王贵强… - Journal of Clinical …, 2022 - search.ebscohost.com
刘丹,姚甜甜,张宇涵,王贵强,王艳 Page 1 !()*+! 基础慢性肝脏疾病对接受免疫检查点抑制剂治疗
的 肿瘤患者的疗效及安全性的影响 刘丹,姚甜甜,张宇涵,王贵强,王艳 北京大学第一医院感染疾病 …
的 肿瘤患者的疗效及安全性的影响 刘丹,姚甜甜,张宇涵,王贵强,王艳 北京大学第一医院感染疾病 …
免疫检查点抑制剂相关乙型肝炎病毒再激活研究进展
雷定佳， 秦波 - 肝脏, 2022 - hepatoday.org
慢性乙型肝炎, 恶性肿瘤是影响全球健康的两大公共问题. 随着新兴抗肿瘤药物免疫检查点抑制
剂(ICIs) 适应证的扩大, 陆续出现了免疫检查点抑制剂(immune checkpoint inhibitors, ICIs) …
剂(ICIs) 适应证的扩大, 陆续出现了免疫检查点抑制剂(immune checkpoint inhibitors, ICIs) …
[HTML][HTML] Hepatitis B virus reactivation in cancer patients undergoing immune checkpoint inhibitors therapy: a systematic review
J Zhao, Y Zhang, S Qin, B Zou, Y Wang - Journal of Cancer, 2022 - ncbi.nlm.nih.gov
Background: Immune checkpoint inhibitor (ICI) therapy is now administered to patients with
advanced cancers. However, the safety and efficacy of ICIs in cancer patients with hepatitis …
advanced cancers. However, the safety and efficacy of ICIs in cancer patients with hepatitis …
[HTML][HTML] Management of hepatitis B in the era of checkpoint inhibition
J Dutcher - Journal for Immunotherapy of Cancer, 2020 - ncbi.nlm.nih.gov
Hepatitis B virus (HBV) is a major global health concern, affecting more than 350 million
people worldwide. Its management in the setting of cancer treatment can be problematic …
people worldwide. Its management in the setting of cancer treatment can be problematic …
Efficacy and safety of immune checkpoint inhibitors in advanced solid tumors with hepatitis B infection.
R Niu, Y Du, H Qian, J Pang, X Zeng, S Chen, J Wang… - 2024 - ascopubs.org
12037 Background: Hepatitis B virus (HBV) infection is related to cirrhosis and
hepatocellular carcinoma (HCC). The breakthroughs of immunotherapy (IO) have …
hepatocellular carcinoma (HCC). The breakthroughs of immunotherapy (IO) have …
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?
SJ De Keukeleire, T Vermassen, ZM Nezhad… - …, 2021 - Taylor & Francis
More patients with chronic hepatitis B and C infection are being exposed to immune
checkpoint inhibitors (ICIs), but the safety and efficacy of ICIs in patients with chronic viral …
checkpoint inhibitors (ICIs), but the safety and efficacy of ICIs in patients with chronic viral …
原发性肝癌免疫检查点抑制剂治疗的进展与挑战.
石琳娜， 隋红 - Practical Oncology Journal, 2020 - search.ebscohost.com
Copyright of Practical Oncology Journal is the property of Journal of Practical Oncology
Editorial Office and its content may not be copied or emailed to multiple sites or posted to a …
Editorial Office and its content may not be copied or emailed to multiple sites or posted to a …
[HTML][HTML] Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors
K Mustafayev, V Mallet… - … of Immunotherapy and …, 2024 - meridian.allenpress.com
Background Patients with cancer with hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection are excluded from many cancer clinical trials of immune checkpoint inhibitors (ICIs) …
infection are excluded from many cancer clinical trials of immune checkpoint inhibitors (ICIs) …